NCPAP


Also found in: Medical.
AcronymDefinition
NCPAPNasal Continuous Positive Airway Pressure
References in periodicals archive ?
Conclusion: Both methods effectively treated NRDS, but PS in combination with NCPAP better improved oxygenation, reduced mortality and incidence of complications.
The proportion of preterm infants at gestation of 25--28 weeks who are managed successfully with NCPAP soon after birth ranges from 45 to 68%, and the proportion of those at gestation 29--32 weeks has been reported to be 64-76%.
The aim of this study was to compare the effect of HFNC and NCPAP in post-extubation of preterm infants with respiratory distress syndrome (RDS) after surfactant administration via INSURE method on the rate of reintubation, duration of oxygen therapy, hospitalization, BPD, IVH, ROP, and mortality in an inborn neonatal intensive care center.
Rates of Utilization and Evidence Supporting the Use of Four Neonatal Respiratory Technologies * Intervention Strength of Self Estimated Evidence Reported General Utilization ** Utilization Early HFOV for Contradictory 74% <6% RDS in neonates HFOV for ARDS Positive but 82% >84% in term infants limited and children NCPAP for Strong 95% >84% neonatal weaning NCPAP to avoid None 95% <16% neonatal intubation * Adapted from Intensive Care Med 2008 Jan; 34(1):174-8).
He randomized 57 patients with suspected obstructive sleep apnea into one of three study arms, each containing 19 patients using NCPAP with internal heated humidification, internal cooled humidification, or no humidification.
TABLE ONE: RATES OF UTILIZATION AND EVIDENCE SUPPORTING THE USE OF FOUR NEONATAL RESPTRATORY TECHNOLODIES * INTERVENTION STRENGTH OF SELF ESTIMATED EVIDENCE REPORTED GENERAL UTILIZATION UTILIZATION EARLY HFOV CONTRADICTORY 74% < 6% FOR RDS IN NEONATES HFOV FOR POSITIVE BUT 82% > 84% ARDS IN TERM LIMITED INFANTS AND CHILDREN NCPAP FOR STRONG 95% > 84% NEONATAL WEANINO NCPAP TO NONE 95% < 16% AVOID NEONATAL INTUBATION * ADAPTED FROM INTENSIVE CARE MED 2008 JAN;34(1);174-8).
The use of NCPAP on its own and in combination with the use of surfactant has been shown to improve the outcomes of HMD in premature infants.
NCPAP reduces the need for surfactant in preterm infants with hyaline membrane disease.